Effect of Atorvastatin, a HMG-CoA Reductase Inhibitor, in Experimental Colitis in Mice
Korean Journal of Pathology
;
: 401-407, 2004.
Artículo
en Inglés
| WPRIM
| ID: wpr-112678
ABSTRACT
BACKGROUND:
The statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are approved for cholesterol reduction, and may also be beneficial in the treatment of inflammatory disease. In this study, atorvastatin was tested in experimental colitis, a disease model of inflammatory bowel disease.METHODS:
To induce colitis, dextran sodium sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS) were administrated to C57BL/6 or BALB/c mice. Mice were monitored daily for loss of body weight and survival for indicated days. Colon length and histology were examined after sacrifice.RESULTS:
The administration of DSS induced marked colonic inflammation and shortening, and resulted in a loss of body weight. DSSinduced colitis was not affected by atorvastatin treatment, but in contrast, the administration of atorvastatin relieved TNBS-induced colitis with a resultant rapid recovery of weight loss and a reduction in colonic length shortening. Histologically, inflammatory cell infiltration in the colonic wall, mucosal ulceration and crypt disruption were also suppressed in atorvastatin treated mice.CONCLUSION:
These results suggest that atorvastatin preserves intestinal integrity in colitis, probably via the modulation of Th cell-mediated immune response, in a manner independent of innate immunity.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Oxidorreductasas
/
Sodio
/
Úlcera
/
Peso Corporal
/
Enfermedades Inflamatorias del Intestino
/
Pérdida de Peso
/
Colesterol
/
Dextranos
/
Coenzima A
/
Colitis
Límite:
Animales
Idioma:
Inglés
Revista:
Korean Journal of Pathology
Año:
2004
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS